Protocol Ledger

NCT05730283 · Phase II · RECRUITING

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Interventional Phase II clinical trial protocol NCT05730283 sponsored by Kevin Winthrop in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-02 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05730283
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05730283
Protocol FieldVerified Registry Value
NCT IdentifierNCT05730283
Consolidated Lead SponsorKevin Winthrop
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2025-06-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI